(Q36693857)

15 August 2017

1 reference

title

Therapeutic options for sleep-maintenance and sleep-onset insomnia (English)

1 reference

15 August 2017

0 references

Anna K Morin

1

1 reference

15 August 2017

Courtney I Jarvis

series ordinal

2

1 reference

15 August 2017

Ann M Lynch

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

volume

27

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

89-110

1 reference

The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Identification and management of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Diagnosis and treatment of chronic insomnia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Sleep disturbances and mood disorders: an epidemiologic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Poor sleep increases the prospective risk for recurrent events in middle-aged women with coronary disease. The Stockholm Female Coronary Risk Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Sleep problems and their correlates in a working population

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Insomnia, health-related quality of life and healthcare resource consumption. A study of managed-care organisation enrollees

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Clinical practice. Chronic insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Use of sleep hygiene in the treatment of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

A systematic review of non-pharmacological therapies for sleep problems in later life

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Cognitive-behavioral group therapy as an early intervention for insomnia: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Subunit composition, distribution and function of GABA(A) receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Positioning of the alpha-subunit isoforms confers a functional signature to gamma-aminobutyric acid type A receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Hypnotic effects of low doses of quazepam in older insomniacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

The effects of flurazepam, lorazepam, and triazolam on sleep and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Sleep Latency Is Shortened During 4 Weeks of Treatment With Zaleplon, a Novel Nonbenzodiazepine Hypnotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Caloric restriction and caloric restriction mimetics: current status and promise for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Sedation and performance impairment of diphenhydramine and second-generation antihistamines: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Clinical evaluation of diphenhydramine hydrochloride for the treatment of insomnia in psychiatric patients: a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Diphenhydramine in insomniac family practice patients: a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Tolerance to daytime sedative effects of H1 antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Efficacy and safety of herbal stimulants and sedatives in sleep disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Effects of exogenous melatonin on sleep: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

The scientific basis for the reputed activity of Valerian

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Valerian for insomnia: a systematic review of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Hepatitis associated with Kava, a herbal remedy for anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Melatonin Treatment for Age-Related Insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, with the GABAA receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

Overview of the therapeutic management of insomnia with zolpidem

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.89

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.1.89

1 reference

15 August 2017

1 reference